# Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers

> **NCT03148925** · PHASE1 · COMPLETED · sponsor: **Selecta Biosciences, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **BIOLOGICAL:** SELA-070
- **BIOLOGICAL:** Saline

## Key facts

- **NCT ID:** NCT03148925
- **Lead sponsor:** Selecta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-11
- **Primary completion:** 2018-10-18
- **Final completion:** 2018-10-18
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03148925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03148925, "Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03148925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*